投融资数据库
免费查数据
注册送3天会员
首页>投融资
MindImmune Therapeutics
A轮
MindImmune Therapeutics, founded in 2016 and based at the University of Rhode Island, is a pharmaceutical company focused on the development of first-in-class drugs that target the immune system to treat diseases of the central nervous system (CNS).In June 2022, MindImmune Therapeutics Inc closed a $12.4-million Series A financing led by Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture and RightHill Ventures.In June 2017, the company secured US $5 million in seed funding to support the launch of the company. In August 2017, the company closed a seed funding. In January 2018, MindImmune closed a second seed financing round
基本信息
-
公司全称MindImmune Therapeutics Inc
-
类型神经退行性疾病治疗产品研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数不明确
-
地址130 Flagg Rd KINGSTON RHODE ISLAND 02881-2015; US; Telephone: +14012254612;
-
联系电话
-
邮箱
-
成立时间2016-01-01
投融资
-
2025-11-24
-
2022-06-13
相关投融资企业
A轮
Engitix LIMITED is a biopharmaceutical company that focuses on the development of therapeutics.In January 2022, Engitix Ltd announced the close of its $54m Series A financing as well as a strategic collaboration with Dompé farmaceutici S.P.A
收并购
Agenus Inc.是一家致力于开发和商业化治疗癌症和传染病疗法的生物技术公司，且主要是基于免疫学疗法。公司的技术组合由 Saponin Platform和Heat Shock Protein Platform组成。在其皂素平台包括QS-21 Stimulon佐剂或QS-21 Stimulon，正处于试验阶段，可用于治疗癌症、带状疱疹、疟疾、阿尔茨海默病、人类免疫缺陷病毒和结核。在HSP平台中正在开发重组系列及前噬菌体系列疫苗。重组系列平台的HerpV疫苗包含了QS-21 Stimulon，可用于治疗生殖器疱疹，已完成了第一阶段试验，正在进行第二阶段试验。在前噬菌体系列中，候选产品已经完成了第3期的临床试验，可用于治疗肾细胞癌。前噬菌体系列中R-100疫苗已在俄罗斯注册，用于治疗患有肾细胞癌的中期患者。此外,前噬菌体系列的g - 100和g - 200疫苗的第二阶段试验已被美国计入测试，可用于治疗神经胶质瘤的反复发作。公司的业务活动包括产品研发、知识产权诉讼、制造、管理和临床事务、企业融资和发展活动、市场开发和支持性合作。公司的候选产品需要临床试验，并经过监管机构的批准,以及市场的接受。公司部分战略是主要通过与学者、企业合作伙伴和授权人共同合作，将候选产品开发并商业化。
该公司最初作为一家特拉华州有限责任公司成立于1994年。
收并购
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases based on repeatome.In September 2021, ROME Therapeutics completed a $77 million Series B financing led by Section 32.By April 2020, the company had raised $50 million in Series A funding
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息